Agios

The post In this issue, we bring you insights from Prof. Khaled Musallam and Prof. Aurelio Maggio on their de-LIGHT (longitudinal investigation of genetic and hematologic determinants of outcomes in β-thalassemia) cohort study collaboration. appeared firs

There's power in the company's No. 1 molecule.

The post In this issue, we bring you excerpts from an interview withDr Antonella Meloni of the Bioengineering Unit, Toscana GabrieleMonasterio Foundation, Pisa, and Dr Paolo Ricchi, Internist fromAzienda Ospedaliera Antonio Cardarelli, Napoli, who are inv

The post To celebrate International Thalassaemia Day 2025, this ThalassemiaNews Special Edition is dedicated to the Thalassaemia International Federation (TIF). appeared first on Agios.

The post In this Issue, we highlight the importance of patient advocacy in the thalassemia community and bring you excerpts from an interview with Craig Butler, National Executive Director of Cooley's Anemia Foundation appeared first on Agios.

The ACTIVATE-Kids study shows mitapivat effectively raises hemoglobin in children with PK deficiency, confirming safety from adult trials.

Shares of Agios Pharmaceuticals collapsed Monday on an unexpected side effect related to the company's thalassemia treatment, mitapivat.

The post In this Issue, we bring you excerpts from an interview with Dr. AIi Amid, co-author of 'Guidelines for the Management of Alpha-Thalassaemia', recently published by the Thalassaemia International Federation (TIF). appeared first on Agios.